Mineralys Therapeutics (MLYS) Financials

Mineralys Therapeutics (NASDAQ: MLYS) remains a pre-revenue biotechnology company with substantial liquidity but continuing operating losses. The company reported no revenue in each presented quarter, while research and development spending remains the primary use of capital. Financial results therefore depend heavily on clinical progress, future financing and the company’s ability to advance its pipeline.

Liquidity has improved significantly since 2023. As of June 30, 2026, Mineralys held $138.3 million in cash and equivalents and $523.1 million in short-term investments, or approximately $661.4 million in cash and investments. That compares with roughly $253.8 million at the end of the third quarter of 2023 and $244.0 million at June 30, 2024. However, much of this improvement came from repeated equity financing rather than internally generated cash.

• Strong liquidity position: Cash and short-term investments totaled approximately $661.4 million at the end of Q2 2026, providing a substantial funding base for clinical development.
• Limited near-term balance-sheet pressure: Current assets of $665.8 million were more than 34 times current liabilities of $19.3 million. The company also reported no commitments and contingencies in the supplied balance-sheet data.
• Operating cash burn improved sequentially: Net cash used in operating activities declined to $32.6 million in Q2 2026 from $39.5 million in Q1 2026 and $37.9 million in Q4 2025.
• Investment income provides some support: Interest and investment income was $5.0 million in Q2 2026, helping offset a portion of operating expenses and reflecting the benefit of the company’s large cash and investment portfolio.
• Financing has been the primary source of liquidity: Mineralys raised $144.2 million through common-equity issuance in Q2 2026, following $20.2 million in Q1 2026 and much larger equity raises in 2025. This supports development but makes the company dependent on capital markets.
• Debt increased during Q2: The balance sheet showed $97.6 million of long-term debt at June 30, 2026, compared with no noncurrent debt in Q1. Investors should review the terms, interest rate and repayment schedule because the supplied statements do not provide those details.
• No commercial revenue has been reported: Revenue was $0 in every supplied income statement. Mineralys currently has no revenue stream to offset research, development and administrative costs.
• Net losses remain substantial: Q2 2026 net loss was $241.1 million, or $2.85 per basic and diluted share, compared with a $39.3 million loss in Q1. The sharp increase was driven primarily by $221.4 million of R&D expense and should be investigated for one-time or non-cash items.
• Research spending is volatile and elevated: R&D expense rose from $24.4 million in Q1 2026 and $38.3 million in the restated Q2 2025 period to $221.4 million in Q2 2026. Although the cash-flow statement included significant non-cash adjustments, this increase materially reduced reported earnings.
• Accumulated losses and dilution are growing: Retained earnings declined to negative $737.6 million by Q2 2026 from negative $388.0 million at June 30, 2025. Weighted-average basic shares rose to 84.7 million in Q2 2026 from 65.5 million in Q2 2025, indicating meaningful dilution for existing shareholders.

Overall, Mineralys has a much stronger liquidity cushion than it had in 2023 and early 2024, but it remains a high-risk, development-stage biotech. The cash balance may provide meaningful runway, yet the company continues to consume cash, reports no revenue, relies on equity financing and has recently added debt. Investors should focus on clinical milestones, the sustainability of the unusually high Q2 R&D expense and whether future funding needs lead to additional dilution.